With 3-year median follow-up , PDQ-39 mobility scores averaged 18 points ( 95 % CI 05-30 , p = 0005 ) better in patients randomly assigned to levodopa than those assigned to levodopa-sparing therapy , with no increase or attrition of benefit during 7 years ' observation .